{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:41:55Z","timestamp":1792636915486,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction<\/jats:title>\n            <jats:p>Recent advancements in systemic chemotherapy have fueled debates regarding the feasibility of combining systemic therapy with surgery for advanced intrahepatic cholangiocarcinoma (ICC). However, the absence of consensus on oncological resectability criteria has hindered discussions on optimal multidisciplinary management. This study sought to propose preoperative oncological resectability criteria for ICC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Patients undergoing upfront curative-intent hepatectomy for ICC were identified from an international multi-institutional database. Independent tumor-related prognostic factors for overall survival were identified by using multivariable Cox regression and utilized to develop resectability criteria.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Among 953 patients, four independent tumor-related predictors of poor prognosis were identified: lymph node metastasis (LNM) on imaging (HR 1.3, 95% confidence interval [CI] 1.07\u20131.59), tumor size &gt;\u20095\u00a0cm (hazard ratio [HR] 1.52, 95% CI 1.25\u20131.85), multinodular lesions (HR 2.03, 95% CI 1.64\u20132.52), and major vascular invasion (HR 1.64, 95% CI 1.34\u20132.01). High-risk points were identified based on a point system associated with the hazards of each factor: 1 point each for LNM, tumor size &gt;\u20095\u00a0cm, and major vascular invasion, and 2 points for multinodular lesions. Patients were categorized as resectable (R) for scores of 0\u20131 or borderline resectable (BR) for scores \u2265\u20092. Patients with BR disease (n\u2009=\u2009385, 40.4%) had markedly worse median overall survival versus individuals with R disease (n\u2009=\u2009568, 59.6%) (24.6\u00a0months vs. 69.7\u00a0months, <jats:italic>p\u2009<\/jats:italic>&lt;\u20090.001). Validation in an external cohort confirmed these findings.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The proposed preoperatively assessable resectability criteria can help differentiate BR versus R disease among ICC patients. These criteria offer a practical framework for preoperative risk stratification, aiding in treatment planning.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1245\/s10434-025-17776-x","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T09:48:44Z","timestamp":1752140924000},"page":"7141-7151","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Oncological Resectability Criteria for Intrahepatic Cholangiocarcinoma: A Preoperative Framework for Multidisciplinary Management"],"prefix":"10.1245","volume":"32","author":[{"given":"Jun","family":"Kawashima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Akabane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selamawit","family":"Woldesenbet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamantis I.","family":"Tsilimigras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Sahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Cauchy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Aucejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo P.","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreia","family":"Rodriguea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Hugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shishir K.","family":"Maithel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas","family":"Groot Koerkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irinel","family":"Popescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Kitago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Martel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Pulitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Aldrighetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Poultsides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ruzzente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd W.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Gleisner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itaru","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7994-9870","authenticated-orcid":false,"given":"Timothy M.","family":"Pawlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"issue":"7","key":"17776_CR1","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s00432-010-0971-z","volume":"137","author":"AK Singal","year":"2011","unstructured":"Singal AK, Vauthey JN, Grady JJ, Stroehlein JR. Intra-hepatic cholangiocarcinoma\u2013frequency and demographic patterns: thirty-year data from the M.D. Anderson Cancer Center. J Cancer Res Clin Oncol. 2011;137(7):1071\u20138. https:\/\/doi.org\/10.1007\/s00432-010-0971-z.","journal-title":"J Cancer Res Clin Oncol."},{"issue":"12","key":"17776_CR2","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1245\/s10434-014-3828-x","volume":"21","author":"AX Zhu","year":"2014","unstructured":"Zhu AX, Borger DR, Kim Y, Cosgrove D, Ejaz A, Alexandrescu S, et al. Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets. Ann Surg Oncol. 2014;21(12):3827\u201334. https:\/\/doi.org\/10.1245\/s10434-014-3828-x.","journal-title":"Ann Surg Oncol."},{"issue":"9","key":"17776_CR3","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557\u201388. https:\/\/doi.org\/10.1038\/s41575-020-0310-z.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"17776_CR4","doi-asserted-by":"publisher","unstructured":"European Association for the Study of the Liver. EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma [published correction appears in J Hepatol. 2023;79(5):1342. https:\/\/doi.org\/10.1016\/j.jhep.2023.09.006].\u00a0J Hepatol. 2023;79(1):181-208.","DOI":"10.1016\/j.jhep.2023.09.006"},{"issue":"7","key":"17776_CR5","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1002\/bjs.10676","volume":"105","author":"XF Zhang","year":"2018","unstructured":"Zhang XF, Beal EW, Bagante F, Chakedis J, Weiss M, Popescu I, et al. Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent. Br J Surg. 2018;105(7):848\u201356. https:\/\/doi.org\/10.1002\/bjs.10676.","journal-title":"Br J Surg."},{"issue":"9","key":"17776_CR6","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1001\/jamasurg.2020.1973","volume":"155","author":"DI Tsilimigras","year":"2020","unstructured":"Tsilimigras DI, Sahara K, Wu L, Moris D, Bagante F, Guglielmi A, et al. Very early recurrence after liver resection for intrahepatic cholangiocarcinoma: considering alternative treatment approaches. JAMA Surg. 2020;155(9):823\u201331. https:\/\/doi.org\/10.1001\/jamasurg.2020.1973.","journal-title":"JAMA Surg."},{"issue":"11","key":"17776_CR7","doi-asserted-by":"publisher","first-page":"6558","DOI":"10.1245\/s10434-023-13809-5","volume":"30","author":"SK Maithel","year":"2023","unstructured":"Maithel SK, Keilson JM, Cao HST, Rupji M, Mahipal A, Lin BS, et al. NEO-GAP: a single-arm, phase II feasibility trial of neoadjuvant gemcitabine, cisplatin, and nab-paclitaxel for resectable High-Risk Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2023;30(11):6558\u201366. https:\/\/doi.org\/10.1245\/s10434-023-13809-5.","journal-title":"Ann Surg Oncol."},{"key":"17776_CR8","doi-asserted-by":"publisher","first-page":"1321683","DOI":"10.3389\/fonc.2024.1321683","volume":"14","author":"SM Ruff","year":"2024","unstructured":"Ruff SM, Pawlik TM. Clinical management of intrahepatic cholangiocarcinoma: surgical approaches and systemic therapies. Front Oncol. 2024;14:1321683. https:\/\/doi.org\/10.3389\/fonc.2024.1321683.","journal-title":"Front Oncol."},{"issue":"8","key":"17776_CR9","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/j.ejso.2019.03.023","volume":"45","author":"S Yadav","year":"2019","unstructured":"Yadav S, Xie H, Bin-Riaz I, Sharma P, Durani U, Goyal G, et al. Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: a propensity score matched analysis. Eur J Surg Oncol. 2019;45(8):1432\u20138. https:\/\/doi.org\/10.1016\/j.ejso.2019.03.023.","journal-title":"Eur J Surg Oncol."},{"issue":"4","key":"17776_CR10","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1245\/s10434-020-09478-3","volume":"28","author":"O Utuama","year":"2021","unstructured":"Utuama O, Permuth JB, Dagne G, Sanchez-Anguiano A, Alman A, Kumar A, et al. Neoadjuvant chemotherapy for intrahepatic cholangiocarcinoma: a propensity score survival analysis supporting use in patients with high-risk disease. Ann Surg Oncol. 2021;28(4):1939\u201349. https:\/\/doi.org\/10.1245\/s10434-020-09478-3.","journal-title":"Ann Surg Oncol."},{"issue":"11","key":"17776_CR11","doi-asserted-by":"publisher","first-page":"6725","DOI":"10.1245\/s10434-020-09536-w","volume":"28","author":"MC Mason","year":"2021","unstructured":"Mason MC, Massarweh NN, Tzeng CD, Chiang YJ, Chun YS, Aloia TA, et al. Time to rethink upfront surgery for resectable intrahepatic cholangiocarcinoma? implications from the neoadjuvant experience. Ann Surg Oncol. 2021;28(11):6725\u201335. https:\/\/doi.org\/10.1245\/s10434-020-09536-w.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"17776_CR12","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.pan.2017.11.011","volume":"18","author":"S Isaji","year":"2018","unstructured":"Isaji S, Mizuno S, Windsor JA, Bassi C, Fern\u00e1ndez-Del Castillo C, Hackert T, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018;18(1):2\u201311. https:\/\/doi.org\/10.1016\/j.pan.2017.11.011.","journal-title":"Pancreatology."},{"issue":"6","key":"17776_CR13","doi-asserted-by":"publisher","first-page":"0","DOI":"10.1159\/000538627","volume":"13","author":"K Akahoshi","year":"2024","unstructured":"Akahoshi K, Shindoh J, Tanabe M, Ariizumi S, Eguchi S, Okamura Y, et al. Oncological resectability criteria for hepatocellular carcinoma in the era of novel systemic therapies: the japan liver cancer association and japanese society of hepato-biliary-pancreatic surgery expert consensus statement 2023. Liver Cancer. 2024;13(6):0\u201310. https:\/\/doi.org\/10.1159\/000538627.","journal-title":"Liver Cancer."},{"issue":"6","key":"17776_CR14","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1159\/000539381","volume":"13","author":"J Shindoh","year":"2024","unstructured":"Shindoh J, Kawamura Y, Akahoshi K, Matsumura M, Okubo S, Akuta N, et al. Clinical utility of the novel oncological criteria of resectability for advanced hepatocellular carcinoma. Liver Cancer. 2024;13(6):601\u20139. https:\/\/doi.org\/10.1159\/000539381.","journal-title":"Liver Cancer."},{"issue":"2","key":"17776_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","volume":"67","author":"MB Amin","year":"2017","unstructured":"Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The Eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging. CA Cancer J Clin. 2017;67(2):93\u20139. https:\/\/doi.org\/10.3322\/caac.21388.","journal-title":"CA Cancer J Clin."},{"issue":"4","key":"17776_CR16","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1159\/000522403","volume":"11","author":"S Kubo","year":"2022","unstructured":"Kubo S, Shinkawa H, Asaoka Y, Ioka T, Igaki H, Izumi N, et al. Liver cancer study group of japan clinical practice guidelines for intrahepatic cholangiocarcinoma. Liver Cancer. 2022;11(4):290\u2013314. https:\/\/doi.org\/10.1159\/000522403.","journal-title":"Liver Cancer."},{"issue":"4","key":"17776_CR17","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1245\/s10434-022-12803-7","volume":"30","author":"Y Endo","year":"2023","unstructured":"Endo Y, Sasaki K, Moazzam Z, Lima HA, Alaimo L, Guglielmi A, et al. Higher tumor burden status dictates the impact of surgical margin status on overall survival in patients undergoing resection of intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2023;30(4):2023\u201332. https:\/\/doi.org\/10.1245\/s10434-022-12803-7.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"17776_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/SLA.0000000000004808","volume":"274","author":"M Nagino","year":"2021","unstructured":"Nagino M, DeMatteo R, Lang H, Cherqui D, Malago M, Kawakatsu S, et al. Proposal of a new comprehensive notation for hepatectomy: the \u201cNew World\u201d terminology. Ann Surg. 2021;274(1):1\u20133. https:\/\/doi.org\/10.1097\/SLA.0000000000004808.","journal-title":"Ann Surg."},{"issue":"2","key":"17776_CR19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205\u201313. https:\/\/doi.org\/10.1097\/01.sla.0000133083.54934.ae.","journal-title":"Ann Surg."},{"issue":"6","key":"17776_CR20","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/(sici)1097-0258(19990330)18:6<681::aid-sim71>3.0.co;2-r","volume":"18","author":"S van Buuren","year":"1999","unstructured":"van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med. 1999;18(6):681\u201394. https:\/\/doi.org\/10.1002\/(sici)1097-0258(19990330)18:6%3c681::aid-sim71%3e3.0.co;2-r.","journal-title":"Stat Med."},{"issue":"7","key":"17776_CR21","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.1245\/s10434-024-15210-2","volume":"31","author":"DI Tsilimigras","year":"2024","unstructured":"Tsilimigras DI, Endo Y, Guglielmi A, Aldrighetti L, Weiss M, Bauer TW, et al. Recurrent intrahepatic cholangiocarcinoma: a 10-point score to predict post-recurrence survival and guide treatment of recurrence. Ann Surg Oncol. 2024;31(7):4427\u201335. https:\/\/doi.org\/10.1245\/s10434-024-15210-2.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"17776_CR22","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/jso.24630","volume":"116","author":"LM Youngwirth","year":"2017","unstructured":"Youngwirth LM, Nussbaum DP, Thomas S, Adam MA, Blazer DG 3rd, Roman SA, et al. Nationwide trends and outcomes associated with neoadjuvant therapy in pancreatic cancer: an analysis of 18 243 patients. J Surg Oncol. 2017;116(2):127\u201332. https:\/\/doi.org\/10.1002\/jso.24630.","journal-title":"J Surg Oncol."},{"issue":"6","key":"17776_CR23","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1002\/hep.31598","volume":"73","author":"A Lamarca","year":"2021","unstructured":"Lamarca A, Santos-Laso A, Utpatel K, La Casta A, Stock S, Forner A, et al. Liver metastases of intrahepatic cholangiocarcinoma: implications for an updated staging system. Hepatology. 2021;73(6):2311\u201325. https:\/\/doi.org\/10.1002\/hep.31598.","journal-title":"Hepatology."},{"issue":"7","key":"17776_CR24","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1001\/jamasurg.2022.1298","volume":"157","author":"S Franssen","year":"2022","unstructured":"Franssen S, Soares KC, Jolissaint JS, Tsilimigras DI, Buettner S, Alexandrescu S, et al. Comparison of hepatic arterial infusion pump chemotherapy vs resection for patients with multifocal intrahepatic cholangiocarcinoma. JAMA Surg. 2022;157(7):590\u20136. https:\/\/doi.org\/10.1001\/jamasurg.2022.1298.","journal-title":"JAMA Surg."},{"issue":"12","key":"17776_CR25","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.1245\/s10434-018-6669-1","volume":"25","author":"S Conci","year":"2018","unstructured":"Conci S, Ruzzenente A, Vigan\u00f2 L, Ercolani G, Fontana A, Bagante F, et al. Patterns of distribution of hepatic nodules (single, satellites or multifocal) in intrahepatic cholangiocarcinoma: prognostic impact after surgery. Ann Surg Oncol. 2018;25(12):3719\u201327. https:\/\/doi.org\/10.1245\/s10434-018-6669-1.","journal-title":"Ann Surg Oncol."},{"issue":"7","key":"17776_CR26","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1245\/s10434-014-4223-3","volume":"22","author":"G Spolverato","year":"2015","unstructured":"Spolverato G, Kim Y, Alexandrescu S, Popescu I, Marques HP, Aldrighetti L, et al. Is hepatic resection for large or multifocal intrahepatic cholangiocarcinoma justified? results from a multi-institutional collaboration. Ann Surg Oncol. 2015;22(7):2218\u201325. https:\/\/doi.org\/10.1245\/s10434-014-4223-3.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"17776_CR27","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.gassur.2023.10.002","volume":"28","author":"J Kawashima","year":"2024","unstructured":"Kawashima J, Sahara K, Shen F, Guglielmi A, Aldrighetti L, Weiss M, et al. Predicting risk of recurrence after resection of stage I intrahepatic cholangiocarcinoma. J Gastrointest Surg. 2024;28(1):18\u201325. https:\/\/doi.org\/10.1016\/j.gassur.2023.10.002.","journal-title":"J Gastrointest Surg."},{"issue":"4","key":"17776_CR28","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/s41379-020-00702-9","volume":"34","author":"K Yugawa","year":"2021","unstructured":"Yugawa K, Itoh S, Yoshizumi T, Iseda N, Tomiyama T, Toshima T, et al. Prognostic impact of tumor microvessels in intrahepatic cholangiocarcinoma: association with tumor-infiltrating lymphocytes. Mod Pathol. 2021;34(4):798\u2013807. https:\/\/doi.org\/10.1038\/s41379-020-00702-9.","journal-title":"Mod Pathol."},{"issue":"5","key":"17776_CR29","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1007\/s11605-020-04720-5","volume":"25","author":"DI Tsilimigras","year":"2021","unstructured":"Tsilimigras DI, Sahara K, Paredes AZ, Moro A, Mehta R, Moris D, et al. Predicting lymph node metastasis in intrahepatic cholangiocarcinoma. J Gastrointest Surg. 2021;25(5):1156\u201363. https:\/\/doi.org\/10.1007\/s11605-020-04720-5.","journal-title":"J Gastrointest Surg."},{"issue":"4","key":"17776_CR30","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1159\/000449339","volume":"5","author":"T Yoh","year":"2016","unstructured":"Yoh T, Hatano E, Yamanaka K, Nishio T, Seo S, Taura K, et al. Is surgical resection justified for advanced intrahepatic cholangiocarcinoma? Liver Cancer. 2016;5(4):280\u20139. https:\/\/doi.org\/10.1159\/000449339.","journal-title":"Liver Cancer."},{"issue":"2","key":"17776_CR31","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/jso.25480","volume":"120","author":"K Sahara","year":"2019","unstructured":"Sahara K, Tsilimigras DI, Mehta R, Bagante F, Guglielmi A, Aldrighetti L, et al. A novel online prognostic tool to predict long-term survival after liver resection for intrahepatic cholangiocarcinoma: the \u201cmetro-ticket\u201d paradigm. J Surg Oncol. 2019;120(2):223\u201330. https:\/\/doi.org\/10.1002\/jso.25480.","journal-title":"J Surg Oncol."},{"issue":"11","key":"17776_CR32","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.3390\/jcm10112426","volume":"10","author":"F Bartsch","year":"2021","unstructured":"Bartsch F, Heuft LK, Baumgart J, Hoppe-Lotichius M, Margies R, Gerber TS, et al. Influence of lymphangio (L), vascular (V), and perineural (Pn) invasion on recurrence and survival of resected intrahepatic cholangiocarcinoma. J Clin Med. 2021;10(11):2426. https:\/\/doi.org\/10.3390\/jcm10112426.","journal-title":"J Clin Med."},{"issue":"11","key":"17776_CR33","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1007\/s00535-018-1469-8","volume":"53","author":"T Orimo","year":"2018","unstructured":"Orimo T, Kamiyama T, Mitsuhashi T, Kamachi H, Yokoo H, Wakayama K, et al. Impact of tumor localization on the outcomes of surgery for an intrahepatic cholangiocarcinoma. J Gastroenterol. 2018;53(11):1206\u201315. https:\/\/doi.org\/10.1007\/s00535-018-1469-8.","journal-title":"J Gastroenterol."},{"issue":"39","key":"17776_CR34","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.2217\/fon-2023-0098","volume":"19","author":"K Merath","year":"2023","unstructured":"Merath K, Tiwari A, Parikh AA, Pawlik TM. Molecular targeted and systemic therapy for intrahepatic cholangiocarcinoma: a multi-disciplinary approach. Future Oncol. 2023;19(39):2607\u201321. https:\/\/doi.org\/10.2217\/fon-2023-0098.","journal-title":"Future Oncol."},{"issue":"1","key":"17776_CR35","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12885-020-6610-4","volume":"20","author":"TO Goetze","year":"2020","unstructured":"Goetze TO, Bechstein WO, Bankstahl US, Keck T, K\u00f6nigsrainer A, Lang SA, et al. Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC\/ECC)\u2014a phase III study of the German registry of incidental gallbladder carcinoma platform (GR)\u2014the AIO\/CALGP\/ACO-GAIN-trial. BMC Cancer. 2020;20(1):122. https:\/\/doi.org\/10.1186\/s12885-020-6610-4.","journal-title":"BMC Cancer."},{"key":"17776_CR36","doi-asserted-by":"publisher","unstructured":"Niger M, Nichetti F, Fornaro L, Pircher C, Morano F, Palermo F, et al. A phase II\/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study [published correction appears in BMC Cancer. 2024;24(1):563. https:\/\/doi.org\/10.1186\/s12885-024-12328-0]. BMC Cancer. 2024;24(1):436. Published 2024 Apr 8.","DOI":"10.1186\/s12885-024-12328-0"},{"issue":"11","key":"17776_CR37","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","volume":"7","author":"AX Zhu","year":"2021","unstructured":"Zhu AX, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, et al. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial. JAMA Oncol. 2021;7(11):1669\u201377. https:\/\/doi.org\/10.1001\/jamaoncol.2021.3836.","journal-title":"JAMA Oncol."},{"issue":"8","key":"17776_CR38","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","volume":"9","author":"DY Oh","year":"2024","unstructured":"Oh DY, He AR, Bouattour M, Okusaka T, Qin S, Chen LT, et al. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024;9(8):694\u2013704. https:\/\/doi.org\/10.1016\/S2468-1253(24)00095-5.","journal-title":"Lancet Gastroenterol Hepatol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17776-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-17776-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17776-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T14:04:34Z","timestamp":1758549874000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-17776-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["17776"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-17776-x","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,9]]},"assertion":[{"value":"3 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}